Cover Image

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Jianhui Zhao, Erxu Xue, Zhanju Liu, Xue Li
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease
by: Jianhui Zhao, et al.
Published: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
by: Jeli Mendoza, et al.
Published: (2024)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
by: Fai Fai Ho, et al.
Published: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
by: Suprabhat Giri, et al.
Published: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
by: Bharati Kochar, et al.
Published: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
by: Jessica A. Fitzpatrick, et al.
Published: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
by: Cristina Rubín de Célix, et al.
Published: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
by: Aurelien Amiot, et al.
Published: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
by: Jessica D. Lee, et al.
Published: (2025)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
by: Mathieu Uzzan, et al.
Published: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
by: A. B. Fons, et al.
Published: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
by: Isabel Carbery, et al.
Published: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
by: A. B. Fons, et al.
Published: (2026)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
by: Sanjay K. Murthy
Published: (2026)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
by: Monica E. W. Derks, et al.
Published: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
by: Anupam Kumar Singh, et al.
Published: (2026)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
by: Matthew D. Coates, et al.
Published: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
by: Marco Vincenzo Lenti, et al.
Published: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
by: Agnes Hiu Yan Ho, et al.
Published: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
by: Stephanie Gold, et al.
Published: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
by: Nicholas Clark, et al.
Published: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
by: Joyce Wing Yan Mak
Published: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
by: Purab Patel, et al.
Published: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
by: Federica Tavaglione, et al.
Published: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
by: Jeffrey D McCurdy, et al.
Published: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
by: Suprabhat Giri, et al.
Published: (2025)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
by: Jane Lim, et al.
Published: (2025)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
by: Kee Huat Chuah, et al.
Published: (2025)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
by: Uma Mahadevan, et al.
Published: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
by: Quinn Goddard, et al.
Published: (2025)

Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
by: Konstantinos Papamichael, et al.
Published: (2024)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
by: Stefano Siboni, et al.
Published: (2026)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
by: José Luis Rueda García, et al.
Published: (2026)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
by: José Luis Rueda García, et al.
Published: (2026)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
by: Lynna Chen, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
by: Chang Liu, et al.
Published: (2026)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
by: Nicolas Richard, et al.
Published: (2025)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
by: Brigida Barberio, et al.
Published: (2026)